Tag: Cancer Drugs

Skolkovo Foundation and AstraZeneca sign a strategic partnership agreement

astrazeneca-skolkovo
Skolkovo Foundation and AstraZeneca, an international biopharmaceutical company, have agreed on a strategic partnership in the area of research and educational activities in Russia. The parties int...

AstraZeneca reported successful clinical trial of lung cancer drug

astrazeneca
AstraZeneca and MedImmune, its global biologics research and development arm, have announced positive results for a trial of its lung cancer drug Imfinzi (durvalumab). The phase III PACIFIC tri...

Epizyme aquired $10 million payment from GSK

gsk
Biopharmaceutical company Epizyme earned a $10 million milestone payment from GlaxoSmithKline (GSK) after the pharma giant launched GLP toxicology studies for a first-in-class methyltransferase inhibi...

European Commission provided approval for Darzalex

janssen
Janssen has announced that its CD38-directed monoclonal antibody Darzalex (daratumumab) has expanded its indication with a thumbs-up from the European Commission (EC) as a combination treatment for mu...

FDA approved new leukemia drug

fda office
The U.S. Food and Drug Administration today approved Rydapt (midostaurin) for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation cal...

Bayer got FDA approval for liver cancer drug

bayer
Bayer announced that the U.S. Food and Drug Administration (FDA) approved Stivarga® (regorafenib) tablets for the second-line treatment of patients with hepatocellular carcinoma (HCC) who have been pr...

Clinical studies of cancer drug by AbbVie are unsuccessful

abbvie
AbbVie, a global biopharmaceutical company, today announced that two Phase 3 studies evaluating veliparib, an investigational, oral poly (adenosine diphosphate -ribose) polymerase (PARP) inhibitor did...

Boehringer intends to create a new generation of immunotherapies

boehringer-ingelheim
Boehringer Ingelheim (BI) is aiming to develop a new generation of cancer immunotherapies, using vaccines, cancer-killing viruses and cell therapies combined with its own checkpoint inhibitor to attac...

The University of Queensland opens a new cancer research facility

cancer-diagnostics
New cancer-fighting drugs could emerge from The University of Queensland in coming years, thanks to a state-of-the-art imaging facility opened on March 28th at Brisbane, Quee...

NICE rejected pancreatic cancer treatment by Shire

shire
The UK’s National Institute for Health and Care Excellence (NICE) finalized its determination that Shire’s Onivyde treatment for advanced pancreatic cancer is not cost-effective, and should not be cov...

Lung cancer drug received approval in China

astrazeneca
AstraZeneca announced that the China Food and Drug Administration (CFDA) has granted marketing authorisation for Tagrisso (osimertinib) 40 mg and 80mg once-daily oral tablets for the treatment of adul...

A unique cancer drug can be tested in Russia soon

research
The scientists at the Institute of Chemical Biology and Fundamental Medicine (ICBFM) of the Siberian Branch of the Russian Academy of Sciences expect to receive in the near future the authorization fr...

Belarus researchers work on a new cancer drug

research
The researchers in Belarus are developing a new drug intended for liver and kidney cancer treatment. This was announced by Elena Kalinichenko, the Deputy Director for Science and Innovation at the Ins...

Lilly reported about clinical trial of breast cancer drug

lilly
Eli Lilly and Company announced that its MONARCH 2 trial of abemaciclib met the primary endpoint of progression-free survival (PFS). The Phase 3 study evaluated abemaciclib, a cyclin-dependent kinase ...

Biocartis received €750,000 grant for MSI test development

research
Molecular diagnostics firm Biocartis won a €750,000 grant (approximately $796,000) from the Flanders Organization for Innovation & Entrepreneurship (VLAIO) to support the development of a fully au...

FDA approved Merck’s pembrolizumab

Merck
Merck / MSD announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy, for the treatment of a...